Loading organizations...
Key people at Hikma.
Hikma Ventures is the strategic venture capital arm of Hikma Pharmaceuticals, investing in innovative digital health and life sciences companies globally. Operating as an evergreen fund, it deploys capital from its parent company, Hikma Pharmaceuticals, with a dedicated fund size of $100 million. The firm actively seeks disruptive technologies across a broad spectrum of therapeutic areas, including advanced drug delivery systems, digital therapeutics, and innovations in clinical trial methodologies. Its investment scope further encompasses solutions for respiratory, CNS, oncology, and autoimmune diseases, alongside chronic conditions such as type II diabetes and hypertension, aiming to address significant unmet medical needs. To date, Hikma Ventures has made over 20 investments in companies developing solutions within these specialized sectors worldwide. The firm was founded in 2015.
Key people at Hikma.
Hikma has 3 tracked investments across 2 companies. The latest tracked deal is $15.0M Series B Extension in HeartVista in September 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 28, 2022 | HeartVista | $15.0M Series B Extension | Hikma | — |
| May 30, 2018 | Propeller Health | $20.0M Other Equity | Salim Haffar | 3M Ventures, Safeguard Scientifics, Social Capital, SR ONE |
| May 1, 2018 | Propeller Health | $20.0M Series D | Aptar Pharma | Array Ventures, Bain Capital Ventures, Bowery Capital, Coelius Capital, Eniac Ventures, Ensemble VC, Ligature, Math Capital, Oceans, Queensbridge Venture Partners, Social Capital, Tribe Capital, Anthony Saleh, Evan Cheng, KIM Perell, LEV Ekster, 3M Ventures, Safeguard Scientifics, SR ONE |
